Current treatments

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. Palumbo A et al. J Clin Oncol. 2014 Jan 21. [Epub ahead of print]. Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Merz M et…

IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib-containing regimens

This paper, written by an expert panel of the International Myeloma Working Group, examines the impact of novel treatments on stem cell collection in myeloma patients. It summarises the available evidence and makes recommendations to address identified issues.

NICE guidance: Improving Supportive and Palliative Care for Adults with Cancer

Following consultation on the scope of the guideline we have decided to retain Improving supportive and palliative care for adults with cancer. The title of the new guideline will be changed to End of life care for adults in the last year of life: service delivery. Where there is overlap between the two guidelines we…